Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/70104
Título: Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: Results from two case-cohort studies
Autores/as: Razquin, Cristina
Ruiz-Canela, Miguel
Clish, Clary B.
Li, Jun
Toledo, Estefania
Dennis, Courtney
Liang, Liming
Salas-Huetos, Albert
Pierce, Kerry A.
Guasch-Ferré, Marta
Corella, Dolores
Ros, Emilio
Estruch, Ramon
Gómez-Gracia, Enrique
Fitó, Montse
Lapetra, Jose
Romaguera, Dora
Alonso-Gómez, Angel
Serra-Majem, Lluis 
Salas-Salvadó, Jordi
Hu, Frank B.
Martínez-González, Miguel A.
Clasificación UNESCO: 3206 Ciencias de la nutrición
320501 Cardiología
Palabras clave: Biomarkers
Cardiovascular Disease
Dietary Intervention
Metabolites
Type 2 Diabetes
Fecha de publicación: 2019
Publicación seriada: Cardiovascular Diabetology 
Resumen: Background: The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. Methods: Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography-tandem mass spectrometry, at baseline and after 1-year of intervention. Results: In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase = 1.26; 95% CI 1.06-1.51) and 2-AAA (HR+1 SD increase = 1.28; 95% CI 1.05-1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. Conclusions: Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003
URI: http://hdl.handle.net/10553/70104
ISSN: 1475-2840
DOI: 10.1186/s12933-019-0958-2
Fuente: Cardiovascular Diabetology, [ISSN 1475-2840], v. 18 (1), (Noviembre 2019)
Colección:Artículos
miniatura
Adobe PDF (911,87 kB)
Vista completa

Citas SCOPUSTM   

29
actualizado el 21-abr-2024

Citas de WEB OF SCIENCETM
Citations

27
actualizado el 25-feb-2024

Visitas

90
actualizado el 02-mar-2024

Descargas

86
actualizado el 02-mar-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.